A double-blind, randomized, fixed-dose trial of fluoxetine vs. amitriptyline in the treatment of major depression complicating Alzheimer's disease



	Full Text (PDF)
	Alert me when this article is cited
	Alert me if a correction is posted
	Citation Map



	Email this article to a Colleague
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new issues of the journal
	Add to My Articles & Searches
	Download to citation manager



	Citing Articles via HighWire
	Citing Articles via Google Scholar



	Articles by Taragano, F. E.
	Articles by Comesana-Diaz, E.
	Search for Related Content



	PubMed Citation
	Articles by Taragano, F. E.
	Articles by Comesana-Diaz, E.

Psychosomatics 1997; 38:246-252
Copyright © 1997 by Academy of Psychosomatic Medicine

ORIGINAL RESEARCH REPORTS

A double-blind, randomized, fixed-dose trial of fluoxetine vs. amitriptyline in the treatment of major depression complicating Alzheimer's disease

FE Taragano, CG Lyketsos, CA Mangone, RF Allegri and E Comesana-Diaz
Neuropsychiatry Group (Siren), CEMIC, Associated Hospital, University of Buenos Aires, Argentina.

The objective of this study was to determine the relative efficacy and safety of fluoxetine and amitriptyline in the treatment of major depression complicating Alzheimer's disease (AD). The sample included 37 patients with AD and major depression. The study design was a double- blind, fixed-dose, randomized clinical trial with 45 days of follow-up. The outcome measures were the Hamilton Depression Rating Scale (Ham-D), the Mini-Mental State Exam (MMSE), and the number of dropouts from each arm of the study. Efficacy was similar for fluoxetine and amitriptyline. At Day 45, there was a mean 9.4-point reduction in Ham-D scores (t[df,62] = 9.68, P < 0.0001) and a 2.4-point mean increase in MMSE scores as compared to baseline (t[df,2] = 2.69, P = 0.009). Eleven (58%) of the amitriptyline-treated patients dropped out, compared with 4 (22%) of the fluoxetine-treated patients (chi 2[df,2] = 8.9, P = 0.017). The authors conclude that antidepressant treatment for major depression complicating AD is effective. While fluoxetine and amitriptyline are equally effective, fluoxetine is better tolerated.

This article has been cited by other articles:

J. O. Brooks and J. C. Hoblyn
Neurocognitive Costs and Benefits of Psychotropic Medications in Older Adults
J Geriatr Psychiatry Neurol, December 1, 2007; 20(4): 199 - 214.
[Abstract] [PDF]

A. T. Blaszczyk and M. Mathys
Treatment of Cognitive Decline and Psychiatric Disturbances Associated With Alzheimer's Dementia
Journal of Pharmacy Practice, February 1, 2007; 20(1): 13 - 28.
[Abstract] [PDF]

J. L. Cummings
Alzheimer's Disease
N. Engl. J. Med., July 1, 2004; 351(1): 56 - 67.
[Full Text] [PDF]

J. D Joss, R. M Burton, and C. A Keller
Memory Loss in a Patient Treated with Fluoxetine
Ann. Pharmacother., December 1, 2003; 37(12): 1800 - 1803.
[Abstract] [Full Text] [PDF]

C. H. Kawas
Early Alzheimer's Disease
N. Engl. J. Med., September 11, 2003; 349(11): 1056 - 1063.
[Full Text] [PDF]

C. G. Lyketsos, L. DelCampo, M. Steinberg, Q. Miles, C. D. Steele, C. Munro, A. S. Baker, J.-M. E. Sheppard, C. Frangakis, J. Brandt, et al.
Treating Depression in Alzheimer Disease: Efficacy and Safety of Sertraline Therapy, and the Benefits of Depression Reduction: The DIADS
Arch Gen Psychiatry, July 1, 2003; 60(7): 737 - 746.
[Abstract] [Full Text] [PDF]

G. T. Grossberg and A. K. Desai
Management of Alzheimer's Disease
J. Gerontol. A Biol. Sci. Med. Sci., April 1, 2003; 58(4): M331 - 353.
[Full Text] [PDF]

D.L. Murman, Q. Chen, M.C. Powell, S.B. Kuo, C.J. Bradley, and C.C. Colenda
The incremental direct costs associated with behavioral symptoms in AD
Neurology, December 10, 2002; 59(11): 1721 - 1729.
[Abstract] [Full Text] [PDF]

J. L. Cummings and G. Cole
Alzheimer Disease
JAMA, May 8, 2002; 287(18): 2335 - 2338.
[Full Text] [PDF]

R. S. Doody, J.C. Stevens, C. Beck, R.M. Dubinsky, J.A. Kaye, L. Gwyther, R.C. Mohs, L.J. Thal, P.J. Whitehouse, S.T. DeKosky, et al.
Practice parameter: Management of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology
Neurology, May 8, 2001; 56(9): 1154 - 1166.
[Abstract] [Full Text] [PDF]

K. L. Lanctôt, N. Herrmann, and P. Mazzotta
Role of Serotonin in the Behavioral and Psychological Symptoms of Dementia
J Neuropsychiatry Clin Neurosci, February 1, 2001; 13(1): 5 - 21.
[Abstract] [Full Text]

C. BARBUI and M. HOTOPF
Amitriptyline v. the rest: still the leading antidepressant after 40 years of randomised controlled trials
The British Journal of Psychiatry, February 1, 2001; 178(2): 129 - 144.
[Abstract] [Full Text] [PDF]

C. G. Lyketsos, J.-M. E. Sheppard, C. D. Steele, S. Kopunek, M. Steinberg, A. S. Baker, J. Brandt, and P. V. Rabins
Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Sertraline in the Treatment of Depression Complicating Alzheimer's Disease: Initial Results From the Depression in Alzheimer's Disease Study
Am J Psychiatry, October 1, 2000; 157(10): 1686 - 1689.
[Abstract] [Full Text]

R. Mayeux and M. Sano
Treatment of Alzheimer's Disease
N. Engl. J. Med., November 25, 1999; 341(22): 1670 - 1679.
[Full Text] [PDF]

O. L. Lopez, S. R. Wisniewski, J. T. Becker, F. Boller, and S. T. DeKosky
Psychiatric Medication and Abnormal Behavior as Predictors of Progression in Probable Alzheimer Disease
Arch Neurol, October 1, 1999; 56(10): 1266 - 1272.
[Abstract] [Full Text] [PDF]

Treating Major Depression in Alzheimer's Disease
Journal Watch Psychiatry, September 1, 1997; 1997(901): 6 - 6.
[Full Text]

Depression Is Treatable in Alzheimer's Patients
Journal Watch Women's Health, June 1, 1997; 1997(601): 21 - 21.
[Full Text]

Get information about faster international access.